title: Nongenomic regulation of chondrocyte membrane fluidity by 1,25-(OH)2D3 and 24,25-(OH)2D3 is dependent on cell maturation.
abstract: 1,25-(OH)2D3 and 24,25-(OH)2D3 regulate rat costochondral chondrocyte cultures in a metabolite-specific manner; 1,25-(OH)2D3 targets primarily growth zone cells (GC) and 24,25-(OH)2D3 targets primarily resting zone cells (RC). Some of the effects are nongenomic, since incubation of isolated membrane fractions with the metabolites results in regulation of enzyme activities comparable to that seen in culture. This study examined whether changes in membrane fluidity might be one mechanism involved in the nongenomic regulatory pathway. Chondrocyte cultures were incubated with the vitamin D metabolites and changes in plasma membrane fluidity monitored using the fluorophore, TMA-DPH, which is specific for membranes exposed to external fluids. Isolated matrix vesicles were also incubated directly with the metabolites and anisotropy of the membrane, as well as alkaline phosphatase-specific activity, determined. 1,25-(OH)2D3 caused a rapid and constant increase in alkaline phosphatase-specific activity in GC matrix vesicles; 24,25-(OH)2D3 caused an increase in RC matrix vesicle enzyme activity that was both dose- and time-dependent. Matrix vesicles produced by GC had a lower degree of fluidity than their parent plasma membranes or RC plasma membranes and matrix vesicles. Fluidity of the GC membrane fractions was increased by 1,25-(OH)2D3 in a dose- and time-dependent manner. 1,25-(OH)2D3 had no effect on the fluidity of the RC membranes. 24,25-(OH)2D3 caused a decrease in fluidity in GC at later time points. This metabolite caused an increase in fluidity of RC plasma membranes that returned to normal levels by 6 h; however, the increase induced in the matrix vesicles remained elevated throughout the 24-h experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Orthopaedics, University of Texas Health Science Center, San Antonio 78284-7774.
authors.forename: L D
authors.initials: LD
authors.lastname: Swain
authors.forename: Z
authors.initials: Z
authors.lastname: Schwartz
authors.forename: K
authors.initials: K
authors.lastname: Caulfield
authors.forename: B P
authors.initials: BP
authors.lastname: Brooks
authors.forename: B D
authors.initials: BD
authors.lastname: Boyan
mesh_terms: D015650:24,25-Dihydroxyvitamin D 3 / Q000494:pharmacology*; D000469:Alkaline Phosphatase / Q000187:drug effects; D000818:Animals; D002117:Calcitriol / Q000494:pharmacology*; D002356:Cartilage / Q000166:cytology / Q000187:drug effects*; D002478:Cells, Cultured; D016922:Cellular Senescence / Q000502:physiology; D004161:Diphenylhexatriene / Q000031:analogs & derivatives; D005456:Fluorescent Dyes; D008560:Membrane Fluidity / Q000187:drug effects*; D051381:Rats
chemical_list: D005456:Fluorescent Dyes; D004161:Diphenylhexatriene; D015650:24,25-Dihydroxyvitamin D 3; C033628:1-(4-(trimethylamino)phenyl)-6-phenylhexa-1,3,5-triene; D000469:Alkaline Phosphatase; D002117:Calcitriol